The purpose of this systematic review and meta-analysis is to explore the factors associated with medication engagement among older adults (≥60 years) with diabetes.
Purpose
The purpose of this systematic review and meta-analysis is to explore the factors associated with medication engagement among older adults (≥60 years) with diabetes.
Methods
Five databases (PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, PsycINFO, and Scopus) were systematically searched to identify studies examining the association between factors and medication engagement among older diabetes patients. A study met inclusion for meta-analysis if the prevalence of medication engagement or factor was reported in ≥2 studies and the frequency or strength of association was either reported or able to be computed. Quality appraisal was performed with the Downs and Black tool.
1.13; 95% CI, 1.00-1.27) was associated with better engagement to diabetes medication.
Conclusions
Of 4 identified factors, 2 are modifiable. Recent policy efforts to decrease the cost burden of prescribed medication for older adults, such as Medicare Part D, may remove this barrier to medication engagement. Routine screening for depression among older adults with diabetes should be included as part of usual care to facilitate an integrated treatment approach. O ne in 4 adults aged ≥65 years in the United States has diabetes. 1 As compared with younger adults with diabetes, older adults are more likely to be prescribed drugs due to the presence of coexisting chronic conditions. 2 In 1 study, older adults with diabetes, on average, were prescribed 8 daily medications. 3 Taking medications each day is difficult. The American Diabetes Association and the American Association of Diabetes Educators recently commissioned a task force to review the use of language to reduce the stigma and negative connotations in the care and treatment of those with diabetes. In its document, recognizing the power of language to promote behavior change, the task force recommended that the word engagement, which implies making a choice to maintain one's health, replace the term adherence, which connotes doing something to please someone else, such as the diabetes care provider. 4 Poor engagement with prescription medications is common, with approximately 58% of adults with diabetes taking <80% of prescribed diabetes medications. 5, 6 Poor medication engagement is associated with negative health outcomes for older adults, such as higher risk of hospitalization, 7, 8 premature mortality, 8 and increased health care costs. [9] [10] [11] By 2040, the population of older adults in the United States is expected to double, from 46.2 million (2014) to 98 million, 12 thereby highlighting the importance of understanding barriers and facilitators of medication engagement among older adults with diabetes.
Over the past 15 years, a number of systematic reviews attempted to identify determinants that contribute to poor medication engagement in diabetes [13] [14] [15] ; however, none restricted its focus to older adults with diabetes. Gellad et al conducted a systematic review to examine barriers to medication engagement among the elderly across chronic conditions. 16 Of 9 studies included in the review, only 2 samples included older adults with diabetes. 17, 18 To date, a comprehensive systematic review to examine evidence regarding factors that affect medication engagement among older adults with diabetes is lacking.
The purpose of this systematic review and metaanalysis was to synthesize evidence from published studies that examined factors associated with medication engagement among older adults with diabetes to identify barriers to and facilitators of medication engagement specific to this population.
Method Search Strategy
Following the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 19 and an a priori protocol registered on PROSPERO (http://www .crd.york.ac.uk/PROSPERO/display_record.asp?ID =CRD42015025799), we searched 5 databases-PubMed, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature), PsycINFO, and Scopus-to identify studies for this review. The first search was conducted in September 2015; it was repeated January 16, 2016, for updates of studies made after the initial search. Because medication engagement is a more recent term, we used the term medication adherence in our search for literature. First, PubMed was searched with the following terms: diabetes, medication adherence, predict*, determin*, barrier*, and facilitat*. The search was not limited by date of publication. The search procedure developed for PubMed was carefully replicated as similarly as possible to retrieve studies from Embase, CINAHL, PsycINFO, and Scopus. The complete lists of search strategies for each database are listed in Appendix A (available online).
A study was eligible for inclusion in the review if it met all of the following criteria: the target population was (1) adults (mean age ≥60 years) with (2) type 1 or type 2 diabetes; (3) the outcome of interest was engagement to either oral diabetes medications or insulin therapy; (4) study results were presented as quantitative data, including the direction and/or magnitude of association between the predicting factors and medication engagement; and (5) the study was original research of observational design (retrospective cohort, prospective cohort, or cross-sectional) published in a peer-reviewed journal and (6) in the English language.
A study was excluded if (1) the study sample was not exclusively older adults with diabetes and the results were not stratified by chronic condition; (2) measurement of medication engagement was not clearly described; (3) the study focused on engagement to medications other than diabetes medications; and (4) the study employed a randomized controlled trial or quasiexperimental design, as these intervention studies usually control all other covariates to examine the causal effects of the intervention.
Study Selection Process
With EndNote reference management software program (version X7), studies retrieved from all databases were collected and duplicate articles eliminated. The complete list of final references was uploaded into the web-based Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) for screening processes. To identify studies meeting eligibility criteria, a 2-stage process was employed: (1) title and abstract screening and (2) full-text assessment. Each study was independently assessed for eligibility by 2 reviewers (the 2 authors), and discrepancies were discussed and resolved by consensus.
Data Extraction
Data were extracted from each study meeting eligibility criteria. The reviewers created a data extraction sheet and piloted it on 2 studies to refine it. Y.J.C. extracted the data from each study, and A.M.S. checked the extracted data. The following information was collected from each study: first author's name; publication year; study design; characteristics of the study sample, including sample size, mean age and sex of subjects, diabetes type, and study setting (country and/or area in which the study was conducted); measurement of medication engagement; and study findings-specifically, factors associated with medication engagement and the direction/ magnitude of the association (eg, regression coefficient [β], odds ratio [OR], or relative risk [RR] for each factor). Identified barriers and facilitators were then categorized as patient, medication, health system, and provider factors with an adapted conceptual framework from Gellad et al. 20 
Study Quality Assessment
Each study was appraised for quality with the Downs and Black 21 instrument developed for randomized and nonrandomized studies. The instrument contains 27 items to evaluate 5 subscales: study reporting, external validity, bias, confounding, and power. Each item can be answered as "yes," "no," or "unable to determine," with a higher score indicating a lower risk of bias. Since this review focused exclusively on observational studies, we modified the instrument by eliminating 8 items relevant to randomized studies (4, 8, 13, 14, 15, 19, 23, and 24) . The modified scale contained 19 items: reporting, 8 items (9 points); external validity, 2 items (2 points); bias, 4 items (4 points); confounding (selection bias), 4 items (4 points); and power, 1 item (1 point). A study meeting all criteria could achieve a score of 20 points. Two reviewers (the 2 authors) independently appraised each study; where they disagreed, the items were discussed and consensus achieved. A study receiving a score ≥18 was considered to be of high quality.
Quantitative Synthesis
A study was eligible for inclusion in the meta-analysis if (1) the proportion of subjects who demonstrated medication engagement or the factor of interest was reported or (2) the strength of association between the factor and medication engagement was reported as an effect size or sample frequency. A specific factor was eligible for metaanalysis if it was reported in a minimum of 2 studies with data reported as specified. Data were extracted as ORs with their 95% CIs [22] [23] [24] [25] [26] [27] [28] [29] [30] or frequency and sample size. [26] [27] [28] [30] [31] [32] [33] [34] [35] Standardized effect sizes were computed. A pooled effect was estimated for prevalence of medication engagement as well as the relationship between medication engagement and the factor of interest with random effects meta-analysis models. Heterogeneity was assessed with Cochran Q and I 2 statistics. We considered heterogeneity to be greater than that expected by chance alone if either the Cochran Q P value was <.05 or the I 2 statistic was ≥50%. 36 If heterogeneity was present, we conducted subgroup analyses to examine characteristics where studies differed: geographic location, sample size, study design, study quality, measurement of medication engagement, and publication year (2002-2011; 2012-present) . To assess for publication bias, we examined funnel plots and performed the Egger's test, 37 with a P value <.05 indicating that publication bias was a concern. Data were analyzed with Comprehensive Meta-Analysis statistical software (Biostat, Inc, Englewood, New Jersey), with results presented as forest plots.
Results
Figure 1 provides detail of each stage of the study selection process. In total, 538 studies were identified from the literature search. Following removal of duplicate articles (n = 198), 340 studies underwent title and abstract review. Of these, 124 studies met criteria for fulltext assessment. Thirty-three studies (7 prospective cohort, 17, 27, 33, [38] [39] [40] [41] 13 retrospective cohort, [23] [24] [25] [26] [29] [30] [31] 35, [42] [43] [44] [45] [46] and 13 cross-sectional 22, 28, 32, 34, [47] [48] [49] [50] [51] [52] [53] [54] [55] ) met all inclusion criteria for the systematic review; of these, 22 studies met criteria for inclusion in the meta-analyses. * Study Quality Figure 2 summarizes the quality appraisal of all included studies. Approximately half (45.4%) were deemed of high quality, achieving ≥18 points. Regarding reporting, each study clearly described the study purpose, main outcomes, and findings. Two studies did not clearly describe the characteristics of the study sample. 29, 41 Approximately 1 in 3 studies clearly compared the distributions of potential confounders between engaged and nonengaged groups.
† Five studies did not report estimates of the random variability for the main outcome measure. 29, 35, 50, 52, 53 One-third of the included studies (n = 10) did not report actual P values.
‡ Regarding external validity, with the exception of 5 studies, 34 ,49,52,54,55 study subjects were representative of the population from which the sample was recruited. Regarding statistical power, only 1 in 5 studies reported estimation of sample size based on an a priori power analysis. 22, 28, [39] [40] [41] 45, 55 Study Characteristics 31, 41 ranging from 60 to 1 101 533. Collectively, the study samples represent data from 2 753 714 adults with diabetes with a mean age ≥60 years. Twelve studies were published within the past 5 years.
||
Medication engagement was measured with prescription refill records (n = 20, 60.6%), ¶ self-report instruments (n = 12, 36.4%), # or dose monitoring (n = 1, 3.0%). 41 Where prescription refill records were used, medication possession ratio (n = 9, 27.3%) 17, 29, 30, 38, [42] [43] [44] [45] 54 was the most frequently used method for medication engagement calculation. The Morisky Medication Adherence Scale (n = 5, 15.2%) 22, 28, 40, 46, 55 was the most frequently used subject self-reported measure of medication engagement. Across studies, medication engagement rates ranged from 31.3% 26 to 84.7%.
47 Table 2 presents the patient, medication, provider, and health system factors studied and their association with medication engagement among older adults with diabetes. Patient and medication factors were the most frequently studied. The majority of associations between patient factors studied and medication engagement were consistent across studies with the exception of age with 5 studies identifying older age as a barrier to 23, 25, 29, 38, 53 and 8 studies identifying older age as a facilitator 22, 24, 30, 31, [39] [40] [41] [42] of medication engagement.
Barriers
High out-of-pocket cost (n = 9, 27.3%), 22 with diabetes. Identified patient-level barriers included female sex (n = 7, 21.2%) 23, 25, [29] [30] [31] 38, 53 ; being of black (n = 4, 12.1%), 31, 38, 40, 53 Hispanic (n = 3, 9.1%) 31, 38, 53 or nonwhite race/ethnicity (n = 1, 3.0%) 24, 52 ; depression or depressive symptoms comorbidity (n = 7, 21.2%) 23, 27, 33, 34, 38, 48, 52 or higher number/severity of comorbidities (n = 4, 12.1%) 17, 25, 31, 44 ; poor knowledge about diabetes self-management (n = 2, 6.1%) 22, 54 ; and poor glycemic control (n = 2, 6.1%). 28, 41 The medication factor, insulin use (n = 3, 9.1%), 17, 22, 23 was associated with poor medication engagement among older adults with diabetes.
Facilitators
The most frequently identified facilitator of medication engagement was mail-order pharmacy use (n = 4, 12.1%), 25, 30, 47, 53 a health system factor. Older patients with diabetes who used mail-order pharmacies were more likely to take their medications as prescribed than were those who used retail pharmacies. Three studies reported that a higher number of prescribed medications (n = 3, 9.1%) 30, 42, 53 was positively associated with medication engagement among older adults with diabetes. Being continuing users of diabetes medication rather than new users (n = 2, 6.1%) 30, 44 and physician communication (n = 1, 3.0%) 51 were facilitators of medication engagement. Older adults with diabetes who had a higher education level (n = 1, 3.0%) 30 were more likely to take their medications as prescribed.
Quantitative Synthesis
The prevalence of diabetes medication engagement among older adults, 3 patient factors (age, female sex, and depression), and 1 health system factor (out-ofpocket costs) were quantitatively synthesized. Sixteen studies reported the prevalence of medication engagement in their respective samples, and 1 732 267 older adults with diabetes who participated in the studies met inclusion for the meta-analysis. According to a random effects model, the proportion of older adults who were more likely to take diabetes medications as prescribed was 64% (95% CI, 60%-67%). Heterogeneity was greater than that expected by chance alone (Cochran Q value = 18 684.4, P < .001; I 2 = 99.9). Of 19 studies that examined the relationship between older age and medication engagement, 9 studies met criteria for inclusion in the meta-analysis. [22] [23] [24] [25] [26] [27] [28] 30, 31 Figure  3A (age) represents data from 1 488 809 older adults with diabetes who participated in the studies. According to a random effects model, older adults were 1.13 times more likely to take diabetes medication as prescribed when compared with the comparison group (OR, 1.13; 95% CI, 1.00-1.27). Heterogeneity was greater than that expected by chance alone (Cochran Q value = 6826.2, P < .001; I 2 = 99.9). Of 15 studies that examined the relationship between sex and medication engagement, 5 met criteria for inclusion in the meta-analysis. 25, 26, 28, 30, 31 Figure 3B (female sex) represents data from 541 176 older adults with diabetes. According to a random effects model, females were 8% less likely to take diabetes medication as prescribed (OR, 0.92; 95% CI, 0.86-0.97) when compared with males, with heterogeneity greater than that expected by chance alone (Cochran Q value = 23.1, P < .001; I 2 = 82.7). Of 10 studies that examined the relationship between depression and medication engagement, 5 met criteria for inclusion in the meta-analysis. 23, 27, [32] [33] [34] Figure 3C (depression) represents data from 22 360 older adults with diabetes who participated in these studies. According to a random effects model, older adults with diabetes who had depression were 27% less likely to take diabetes medications as prescribed (OR, 0.73; 95% CI, 0.62-0.87). Heterogeneity was not greater than that expected by chance alone (Cochran Q value = 6.8, P = .14; I 2 = 41.6).
Of 9 studies that examined the relationship between high out-of-pocket pharmacy costs and medication engagement among older adults with diabetes, 6 met criteria for inclusion in the meta-analysis. [22] [23] [24] [25] 30, 35 Figure  4 represents data from 390 074 older adults who participated in these studies. According to a random effects model, older adults with high out-of-pocket pharmacy costs were 13% less likely to take medication as prescribed (OR, 0.87; 95% CI, 0.80-0.94). Heterogeneity was greater than that expected by chance alone (Cochran Q value = 1396.8, P < .001; I 2 = 99.6). Table 3 presents results of the subgroup analyses. The pooled results for prevalence of medication engagement, older age, female sex, and out-of-pocket pharmacy costs were explored by geographic location of the study, sample size, study design, study quality, the metric used for medication engagement measurement, and year of study publication to identify factors that may have contributed to heterogeneity. Heterogeneity of the pooled prevalence of medication engagement can be explained, in part, by 3 variables: country where the study was conducted, study design, and medication engagement measurement. Of the variables studied, none helped to explain the heterogeneity identified for older age and female sex. Heterogeneity of the association between medication engagement and out-of-pocket pharmacy costs can be explained, in part, by 4 variables: country where the study was located, study sample size, study design, and medication engagement measurement.
We examined funnel plots for medication engagement prevalence, older age, female sex, depression, and outof-pocket pharmacy costs (see Appendix B). Publication bias as assessed with the Egger's test was not a concern (all P values >.05).
Discussion
This systematic review synthesized findings from 33 studies that examined factors associated with diabetes medication engagement among adults ≥60 years to identify barriers and facilitators to medication engagement in this population. Studies were overall of good quality. Of 22 factors studied, the majority were patient factors, with medication and health system factors less frequently studied. Four factors met criteria for pooled results via meta-analysis: older age, female sex, depression, and out-of-pocket costs.
In this study, older age was a facilitator of medication engagement, with older adults 1.13 times more likely than the comparison group to take medication as prescribed. The medication engagement rate of the study sample was reported in approximately half the studies included in the systematic review and ranged between 31.3% and 84.7%, with pooled medication engagement across studies approximately 65%. This is higher than that reported in studies of younger adults with diabetes 5, 6 and is consistent with our pooled finding of older age being a facilitator of medication engagement.
Older adults with diabetes who were female or had comorbid depression were 8% and 27% less likely to take diabetes medication as prescribed when compared with men or those without depression, respectively. Prior systematic reviews and meta-analyses exploring the association between depression and medication engagement among adults with 15, 56 and without 57 diabetes consistently demonstrated the negative association between depression and medication engagement. This may be explained by the influence of depression on impairments in interpersonal relationships and lack of self-care, 56 which may contribute to poor medication engagement. In the Manteuffel et al 58 study examining the relationship of female sex with medication engagement, women were less likely to take medication as prescribed regardless of health condition, which is consistent with our findings. Several plausible explanations, such as sex disparity in medication side effects, roles within family, and beliefs/ concerns about medications, have been explored on the basis of sex differences in patterns of poor medication engagement. 58, 59 Figure 4. Health system factor associated with medication engagement among older adults with diabetes. Squares represent odds ratios of studies, with extended lines denoting 95% CIs. Sizes of squares indicate the relative weight of each study based on its sample size within a random effect meta-analysis model. The diamond represents the estimated pooled odds ratio. High out-of-pocket cost for prescription drugs, a health system factor, was a barrier to medication engagement. Our pooled finding suggests that older adults with diabetes who had higher out-of-pocket costs were 13% less likely to take diabetes medications as prescribed when compared with those with lower pharmacy spending. This finding is consistent with that of previous reviews 13, 15 and suggests that high out-of-pocket costs remain a significant issue for older adults with diabetes, despite implementation of policy initiatives such as Medicare Part D, which provides prescription drug coverage for Medicare beneficiaries lacking other prescription drug coverage. A recent study of older adults with diabetes who participated in the Medical Expenditure Panel Survey showed that while Medicare Part D lowered the financial burden for prescription drugs, approximately 2 of 5 beneficiaries with diabetes experienced the coverage gap in 2011. 60 Therefore, continued efforts to lower out-of-pocket pharmacy costs may be a key health policy implication to improve medication engagement among older adults with diabetes.
A few factors related to medication engagement remain understudied: cognitive impairment, 27 social deprivation, 26 social support, 55 physician communication, 51 and frequency of consultation with the health care providers. 50 Cognitive impairment among older adults is closely associated with lack of understanding and may lead to high risk of unintentional poor medication engagement. Recent studies showed that diabetes can increase the effects of aging on cognitive decline and that improved blood glucose control may delay cognitive decline. [61] [62] [63] [64] In addition, older adults may be socially deprived because of retirement, and this may be related to a lack of social support. Communication between patients and providers may encourage patients to follow their treatment plans, which may lead to medication engagement. Further research is necessary to examine the association between medication engagement and these factors.
Conclusions and Implications for Diabetes Educators
To our knowledge, this is the first systematic review and meta-analysis to study factors associated with medication engagement among older adults with diabetes. These findings should be interpreted conservatively because our literature search was restricted to studies published in the English language and in peer-reviewed journals. Gray literature was not included. Despite these limitations, this work adds to the growing body of research about older adults, a special and growing population of those affected by diabetes.
Diabetes educators should be alert to assess medication engagement among their older adults with diabetes and to evaluate which factors discourage them to take their medications as prescribed. The findings of this systematic review and meta-analysis suggest that older age itself is not a barrier to medication engagement and that other identified factors are potentially modifiable.
Incorporating ongoing assessment of depression into the routine care of older adults with diabetes should be considered for better medication engagement. In addition, lowering the burden of out-of-pocket costs may improve medication engagement in this population. Current policy efforts to reduce prescribed medication costs for older adults, such as Medicare Part D, were especially effective for medically underserved populations, including women and racial ethnic minorities. 60 Diabetes educators need to suggest that their older patients seek out the most affordable prescription drugs according to their prescription drug coverage.
